Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab

Consortium for Improving Survival of Lymphoma (CISL) study

Sung Yong Oh, Won Seog Kim, Jinseok Kim, Seok Jin Kim, Suee Lee, Dae Ho Lee, Jong Ho Won, In Gyu Hwang, Min Kyoung Kim, Soon Il Lee, Yee Soo Chae, Deok Hwan Yang, Hye Jin Kang, Chul Won Choi, Jinny Park, Hyo Jung Kim, Jung Hye Kwon, Ho Sup Lee, Gyeong Won Lee, Hyeon Seok Eom & 3 others Jae Yong Kwak, Cheolwon Suh, Hyo Jin Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Stage IV marginal zone B-cell lymphomas (MZL) are detected in more than 25% of lymphoma patients. In this study, we conducted retrospective analyses of specific cases of stage IV MZL in order to assess their clinical features, as well as the treatments and prognoses of these cases. A total of 94 patients with histological diagnosis of stage IV-MZL from 17 different institutions in Korea were included. Multiple-mucosa-associated lymphoid tissue (MALT)-organs-involved MZL (M-MZL) was detected in 34 patients (36.2%). Bone-marrow-involved stage IV MZL (BM-MZL) was detected in 33 patients (35.1%). Median time to progression (TTP) was 2.4 years (95% CI, 1.9-2.9). Five- and 10-year overall survival rates were 84.5% and 79.8%, respectively. Patients with lymph node involvement in stage IV MZL appeared to have worse prognoses in TTP (P = 0.015). Thirty-one patients were treated with a regimen including rituximab (CTx-R[+]), and 31 with a regimen that did not include rituximab (CTx-R[-]). The CTx-R(+) group showed better responses than the CTx-R(-) group (83.9%versus 54.8%, P = 0.026). However, no differences in TTP duration were detected (P = 0.113). Stage IV MZL tend to follow an indolent disease course. Therefore, lymph node involvement is a more valuable prognostic factor for TTP. Rituximab appears to contribute to better responses, but not in cases of TTP. (Cancer Sci 2010; 101: 2443-2447)

Original languageEnglish
Pages (from-to)2443-2447
Number of pages5
JournalCancer Science
Volume101
Issue number11
DOIs
Publication statusPublished - 2010 Nov 1

Fingerprint

Marginal Zone B-Cell Lymphoma
Lymphoma
Survival
Lymph Nodes
Lymphoid Tissue
Korea
Rituximab
Mucous Membrane
Survival Rate
Bone Marrow
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Oh, Sung Yong ; Kim, Won Seog ; Kim, Jinseok ; Kim, Seok Jin ; Lee, Suee ; Lee, Dae Ho ; Won, Jong Ho ; Hwang, In Gyu ; Kim, Min Kyoung ; Lee, Soon Il ; Chae, Yee Soo ; Yang, Deok Hwan ; Kang, Hye Jin ; Choi, Chul Won ; Park, Jinny ; Kim, Hyo Jung ; Kwon, Jung Hye ; Lee, Ho Sup ; Lee, Gyeong Won ; Eom, Hyeon Seok ; Kwak, Jae Yong ; Suh, Cheolwon ; Kim, Hyo Jin. / Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab : Consortium for Improving Survival of Lymphoma (CISL) study. In: Cancer Science. 2010 ; Vol. 101, No. 11. pp. 2443-2447.
@article{a2158c691f3044e1946bb3db4f9876f1,
title = "Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study",
abstract = "Stage IV marginal zone B-cell lymphomas (MZL) are detected in more than 25{\%} of lymphoma patients. In this study, we conducted retrospective analyses of specific cases of stage IV MZL in order to assess their clinical features, as well as the treatments and prognoses of these cases. A total of 94 patients with histological diagnosis of stage IV-MZL from 17 different institutions in Korea were included. Multiple-mucosa-associated lymphoid tissue (MALT)-organs-involved MZL (M-MZL) was detected in 34 patients (36.2{\%}). Bone-marrow-involved stage IV MZL (BM-MZL) was detected in 33 patients (35.1{\%}). Median time to progression (TTP) was 2.4 years (95{\%} CI, 1.9-2.9). Five- and 10-year overall survival rates were 84.5{\%} and 79.8{\%}, respectively. Patients with lymph node involvement in stage IV MZL appeared to have worse prognoses in TTP (P = 0.015). Thirty-one patients were treated with a regimen including rituximab (CTx-R[+]), and 31 with a regimen that did not include rituximab (CTx-R[-]). The CTx-R(+) group showed better responses than the CTx-R(-) group (83.9{\%}versus 54.8{\%}, P = 0.026). However, no differences in TTP duration were detected (P = 0.113). Stage IV MZL tend to follow an indolent disease course. Therefore, lymph node involvement is a more valuable prognostic factor for TTP. Rituximab appears to contribute to better responses, but not in cases of TTP. (Cancer Sci 2010; 101: 2443-2447)",
author = "Oh, {Sung Yong} and Kim, {Won Seog} and Jinseok Kim and Kim, {Seok Jin} and Suee Lee and Lee, {Dae Ho} and Won, {Jong Ho} and Hwang, {In Gyu} and Kim, {Min Kyoung} and Lee, {Soon Il} and Chae, {Yee Soo} and Yang, {Deok Hwan} and Kang, {Hye Jin} and Choi, {Chul Won} and Jinny Park and Kim, {Hyo Jung} and Kwon, {Jung Hye} and Lee, {Ho Sup} and Lee, {Gyeong Won} and Eom, {Hyeon Seok} and Kwak, {Jae Yong} and Cheolwon Suh and Kim, {Hyo Jin}",
year = "2010",
month = "11",
day = "1",
doi = "10.1111/j.1349-7006.2010.01698.x",
language = "English",
volume = "101",
pages = "2443--2447",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "11",

}

Oh, SY, Kim, WS, Kim, J, Kim, SJ, Lee, S, Lee, DH, Won, JH, Hwang, IG, Kim, MK, Lee, SI, Chae, YS, Yang, DH, Kang, HJ, Choi, CW, Park, J, Kim, HJ, Kwon, JH, Lee, HS, Lee, GW, Eom, HS, Kwak, JY, Suh, C & Kim, HJ 2010, 'Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study', Cancer Science, vol. 101, no. 11, pp. 2443-2447. https://doi.org/10.1111/j.1349-7006.2010.01698.x

Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab : Consortium for Improving Survival of Lymphoma (CISL) study. / Oh, Sung Yong; Kim, Won Seog; Kim, Jinseok; Kim, Seok Jin; Lee, Suee; Lee, Dae Ho; Won, Jong Ho; Hwang, In Gyu; Kim, Min Kyoung; Lee, Soon Il; Chae, Yee Soo; Yang, Deok Hwan; Kang, Hye Jin; Choi, Chul Won; Park, Jinny; Kim, Hyo Jung; Kwon, Jung Hye; Lee, Ho Sup; Lee, Gyeong Won; Eom, Hyeon Seok; Kwak, Jae Yong; Suh, Cheolwon; Kim, Hyo Jin.

In: Cancer Science, Vol. 101, No. 11, 01.11.2010, p. 2443-2447.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Stage IV marginal zone B-cell lymphoma - prognostic factors and the role of rituximab

T2 - Consortium for Improving Survival of Lymphoma (CISL) study

AU - Oh, Sung Yong

AU - Kim, Won Seog

AU - Kim, Jinseok

AU - Kim, Seok Jin

AU - Lee, Suee

AU - Lee, Dae Ho

AU - Won, Jong Ho

AU - Hwang, In Gyu

AU - Kim, Min Kyoung

AU - Lee, Soon Il

AU - Chae, Yee Soo

AU - Yang, Deok Hwan

AU - Kang, Hye Jin

AU - Choi, Chul Won

AU - Park, Jinny

AU - Kim, Hyo Jung

AU - Kwon, Jung Hye

AU - Lee, Ho Sup

AU - Lee, Gyeong Won

AU - Eom, Hyeon Seok

AU - Kwak, Jae Yong

AU - Suh, Cheolwon

AU - Kim, Hyo Jin

PY - 2010/11/1

Y1 - 2010/11/1

N2 - Stage IV marginal zone B-cell lymphomas (MZL) are detected in more than 25% of lymphoma patients. In this study, we conducted retrospective analyses of specific cases of stage IV MZL in order to assess their clinical features, as well as the treatments and prognoses of these cases. A total of 94 patients with histological diagnosis of stage IV-MZL from 17 different institutions in Korea were included. Multiple-mucosa-associated lymphoid tissue (MALT)-organs-involved MZL (M-MZL) was detected in 34 patients (36.2%). Bone-marrow-involved stage IV MZL (BM-MZL) was detected in 33 patients (35.1%). Median time to progression (TTP) was 2.4 years (95% CI, 1.9-2.9). Five- and 10-year overall survival rates were 84.5% and 79.8%, respectively. Patients with lymph node involvement in stage IV MZL appeared to have worse prognoses in TTP (P = 0.015). Thirty-one patients were treated with a regimen including rituximab (CTx-R[+]), and 31 with a regimen that did not include rituximab (CTx-R[-]). The CTx-R(+) group showed better responses than the CTx-R(-) group (83.9%versus 54.8%, P = 0.026). However, no differences in TTP duration were detected (P = 0.113). Stage IV MZL tend to follow an indolent disease course. Therefore, lymph node involvement is a more valuable prognostic factor for TTP. Rituximab appears to contribute to better responses, but not in cases of TTP. (Cancer Sci 2010; 101: 2443-2447)

AB - Stage IV marginal zone B-cell lymphomas (MZL) are detected in more than 25% of lymphoma patients. In this study, we conducted retrospective analyses of specific cases of stage IV MZL in order to assess their clinical features, as well as the treatments and prognoses of these cases. A total of 94 patients with histological diagnosis of stage IV-MZL from 17 different institutions in Korea were included. Multiple-mucosa-associated lymphoid tissue (MALT)-organs-involved MZL (M-MZL) was detected in 34 patients (36.2%). Bone-marrow-involved stage IV MZL (BM-MZL) was detected in 33 patients (35.1%). Median time to progression (TTP) was 2.4 years (95% CI, 1.9-2.9). Five- and 10-year overall survival rates were 84.5% and 79.8%, respectively. Patients with lymph node involvement in stage IV MZL appeared to have worse prognoses in TTP (P = 0.015). Thirty-one patients were treated with a regimen including rituximab (CTx-R[+]), and 31 with a regimen that did not include rituximab (CTx-R[-]). The CTx-R(+) group showed better responses than the CTx-R(-) group (83.9%versus 54.8%, P = 0.026). However, no differences in TTP duration were detected (P = 0.113). Stage IV MZL tend to follow an indolent disease course. Therefore, lymph node involvement is a more valuable prognostic factor for TTP. Rituximab appears to contribute to better responses, but not in cases of TTP. (Cancer Sci 2010; 101: 2443-2447)

UR - http://www.scopus.com/inward/record.url?scp=78049451784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049451784&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2010.01698.x

DO - 10.1111/j.1349-7006.2010.01698.x

M3 - Article

VL - 101

SP - 2443

EP - 2447

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 11

ER -